KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Assets: 2017-2024

Historic Current Assets for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $8.1 billion.

  • Moderna's Current Assets fell 31.74% to $6.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 billion, marking a year-over-year decrease of 31.74%. This contributed to the annual value of $8.1 billion for FY2024, which is 21.56% down from last year.
  • Per Moderna's latest filing, its Current Assets stood at $8.1 billion for FY2024, which was down 21.56% from $10.3 billion recorded in FY2023.
  • Over the past 5 years, Moderna's Current Assets peaked at $16.1 billion during FY2021, and registered a low of $6.3 billion during FY2020.
  • Over the past 3 years, Moderna's median Current Assets value was $10.3 billion (recorded in 2023), while the average stood at $10.6 billion.
  • Its Current Assets has fluctuated over the past 5 years, first spiked by 457.94% in 2020, then declined by 23.13% in 2023.
  • Over the past 5 years, Moderna's Current Assets (Yearly) stood at $6.3 billion in 2020, then surged by 155.18% to $16.1 billion in 2021, then declined by 16.43% to $13.4 billion in 2022, then declined by 23.13% to $10.3 billion in 2023, then fell by 21.56% to $8.1 billion in 2024.